• Theralac Restore. Regularity. Immunity. Energy.
    Restore
    Regularity
    Immunity
    Energy
    Theralac Bottle

Theralac® Probiotic Supplement

Theralac is a powerful probiotic that supports digestive and immune health*.  It is formulated to effectively colonize both the small and large intestine.  Theralac has seven U.S. Patents that protect the technology to deliver the probiotic strains deep into the digestive tract and stimulate them with the special prebiotic: Lactostim.  The probiotic strains themselves were carefully selected and are backed with significant scientific research*.

What's inside Theralac?

What's insdie a Theralac Capsule

Five Probiotic Strains:

  • Lactobacillus acidophilus – 10 billion CFU (Strain LA-1)
  • Lactobacillus paracasei – 5 billion CFU (Strain LPC-37)
  • Lactobacillus rhamnosus – 2 billion CFU (Strain LR-32)
  • Bifidobacterium lactis – 10 billion CFU (Strain BL-04)
  • Bifidobacterium lactis – 3 billion CFU (Strain Bi-07)

Other ingredients:

  • Microcrystalline Cellulose – A food-grade, plant cellulose used to standardize the probiotic strength.
  • Sodium Alginate – Provides protection from stomach acid and is a probiotic-preferred source of prebiotic fiber (Protected by 2 US Patents)[1].
  • HPMC (hydroxypropyl methylcellulose) – A derivative of plant cellulose which comprises the capsules.
  • Tri-Sodium Phosphate – Food grade buffer that assures proper pH control.
  • Magnesium Stearate – It is used to fill the capsules and ensures a uniform mixture of all ingredients. A pharmaceutical grade, vegetable source is used in Theralac. Magnesium Stearate has been safely used in capsules and tablets for over 75 years.
  • Silicon Dioxide – Reduces moisture and improves shelf life. Silicon dioxide, or silica for short, is a micronutrient in human nutrition; a food grade source is used in Theralac.
  • Calcium Silicate – Anti-caking agent.
  • Ascorbic Acid – Antioxidant.
  • LactoStim (Sunflower Lecithin and Oleic Acid) – Our patented prebiotic. LactoStim stimulates probiotic growth by providing a food source to the probiotics as soon as they arrive in your digestive tract. Only food grade Lecithin and Oleic Acid are used in Theralac (Protected by 5 US Patents)[2].

Allergy Statement

Theralac contains no: milk, eggs, gluten, wheat, soy, casein, nuts, seafood, or beef products.

[1] US Patents #7,122,370; 7,229,818
[2] US Patents #8,105,577; 8,105,576; 8,491,919; 8,449,878; 8,444,967

Dosage Recommendations for Theralac

Standard Program

Best starting program for most adults.

  • One capsule daily for 2 weeks followed by two capsules per week thereafter.
  • 30 capsules lasts 10 weeks.

Health Maintenance Program

Good for young adults, athletes and persons on physical fitness programs. Can be used by anyone after the standard program.

  • Two capsules weekly for 15 weeks. (Take one every capsule every three days).
  • 30 capsules lasts 15 weeks

Intensive Program

  • Two capsules daily for 15 days.
  • 30 capsules lasts 15 days.

Extreme Programs

Program #1 For Occasional Diarrhea:

  • LOADING DOSE: Take three (3) Theralac capsules nightly for three (3) nights.
  • FOLLOWUP DOSE: Take two (2) Theralac capsules/day continuously until symptoms improve, then one (1) capsule daily.

Program #2 For Occasional Constipation:

  • LOADING DOSE: Take two (2) Theralac capsules nightly for ten (10) nights with 400-800 mg magnesium citrate each night.
  • FOLLOWUP DOSE: Take two (2) Theralac/day continuously until symptoms improve, then move one (1) capsule daily.

** Doctor Russell Blaylock recommends 2-3 capsules twice a day when taking antibiotics.

Questions About Theralac?

We've compiled a list of questions that are commonly asked about Theralac. For general questions, please refer to our Frequently Asked Questions page or, if you can't find what you're looking for, contact us directly.

Probiotics are beneficial bacteria that are able to colonize the intestinal tract and help promote healthy structure and function; Lactobacillus acidophilus is an example of a well known probiotic.

Yes, but much more...Theralac capsules contain 10 billion CFU of Lactobacillus acidophilus (LA-1 strain), a well documented, bile tolerant strain with a long history of use in human dietary supplements. This makes Theralacfive times stronger in "Acidophilus" than most probiotic products. Additionally, Theralac contains 30 billion CFU of four symbiotic probiotics that go beyond the capability of Acidophilus: These are select strains of Lactobacillus and Bifidobacterium species that are backed by scientific studies. Only Theralac contains this blend of well researched probiotic strains.

CFU stands for Colony Forming Unit. It's the number of bacterial colonies that form on a petri dish and indicates a product's viability or strength. Your intestinal tract contains over 100 trillion microorganisms from about 1,000 different species, mostly bacteria. Only high potency probiotic products (those containing 10 billion CFU/capsule or more) can reliably re-establish the probiotic population within this huge number.

Quite common! Many lifestyle factors favor undesirable microorganisms over probiotics in your intestinal tract: stress, poor diet (sugar and fat), alcohol, prescription drugs, travel, frequent colds or infections, and aging are the big ones. It's hard for a modern person not to have a probiotic deficiency to some degree.

They vary from person to person but may include one or more of the following: Constipation or diarrhea, indigestion, incomplete digestion, heartburn, excess gas and bloating, lactose intolerance, weak immune response (frequent colds and infections), fatigue, low energy, muscle weakness, and food allergies. Obviously, you cannot be at peak health if you have a probiotic deficiency!

No. Theralac's advanced, high potency formulation allows you to take two capsules per week once your intestinal tract's microflora has been balanced (this occurs for most people after taking Theralac daily for two weeks). The ability to take a probiotic twice a week provides convenience and cost savings.  On the maintenance dose a bottle of Theralac can last up to 4 months and cost less than $3.00 a week!

NOTE: Taking Theralacdaily for two weeks provides 560 billion CFU to your intestinal tract, a very effective dose by probiotic standards. Once this dose colonizes the intestinal tract it can be maintained by taking two capsules (80 billion CFU) per week.

A food grade substance that benefits probiotic bacteria by some specific mechanism.

Theralac contains two prebiotics that are effective at low dosages; LactoStim® and Sodium Alginate. LactoStim is a food grade emulsifier that stimulates the growth and reproduction of Theralac's probiotic bacteria; and, unlike FOS and other prebiotics, it works in milligram quantities! 

Yes. FOS, or fructooligosaccharides, are prebiotics that you can get by eating certain foods, and are required in larger quantities compared  LactoStim. FOS can cause gas in some individuals when taken as an isolated prebiotic.  When taken in food, the unidentified nutrient factors help reduce the gas issue.  For the best prebiotic, take TruFiber®.

The following foods contain a unique source of soluble fiber (FOS) that stimulates probiotic bacteria. Eat some when you take Theralac!

FoodFOS
Garlic1.0%
Honey1.0%
Rye Bread0.6%
Brown Sugar0.4%
Asparagus0.4%
Bananas0.3%
Onions0.3%
Barley0.2%
Tomatoes0.2%

The probiotic bacteria in Theralac attach to the soft lining (wall) of your intestinal tract and help keep it healthy. The Lactobacillus ("lacto") strains are most active in the small intestine while the Bifidobacterium ("bifido") strains work best in the large intestine (colon). A healthy intestinal wall encourages optimum absorption of nutrients including vitamins and minerals which supports healthy digestion and elimination. Theralac also confers benefits your immune system.

Theralac's five probiotic strains work together (in symbiosis) to stimulate the mucosal immune system on the intestinal surface which then sends activation signals to the body's systemic immune system. Because Theralac's strains are beneficial this action is gentle and modulated. The immune system is put on "yellow alert," so to speak, ready to act quickly when pathogenic microorganisms appear.

Improved elimination and regularity: softer and more predictable bowel movements followed by more energy and intestinal comfort.

Either way works well due to Theralac's acid-proof formulation. Take Theralac with water, fruit juice or milk.

Much better and safer! Most enteric coated probiotics are treated with a polymer of acrylic acid, a synthetic chemical. The sodium alginate used to acid-proof Theralac capsules is a natural carbohydrate found in kelp (patented). Note: studies show that more than 99% of unprotected probiotics are killed when exposed to stomach acid for 1 hour which is the typical amount of time anything you ingest spends in the stomach.

Yes. Take the antibiotic at the prescribed time followed by Theralac two or three hours later. Continue taking Theralac daily for at least two weeks after finishing the antibiotics.

Take at least one per day. When traveling to developing countries take two per day, one in the morning and one in the evening. Intestinal problems are easier to prevent than treat so start taking Theralac daily one week before you leave.

Theralac can be held at room temperature (65°-75° F) for up to 30 days without loss in viability. Keep bottle tightly closed and out of direct sunlight.

Lactose intolerance results from a lack of the enzyme lactase in the small intestine. All five of Theralac's probiotic strains produce lactase and may reduce the severity of lactose intolerance.

The body absorbs vitamins and minerals in the small intestine. The health and integrity of the intestinal soft lining (wall or mucosa) affects the absorption of all nutrients. Theralac may help improve vitamin and mineral absorption by maintaining a healthy soft lining. In addition, mineral absorption, especially calcium and magnesium, is improved by a slightly acidic pH at the mucosal surface. The probiotic strains in Theralac produce lactic and acetic acids which lower pH (acidify); if this occurs on the surface of the soft lining, it may enhance Calcium and Magnesium absorption.

What would be the effect? Probiotic bacteria, including those in Theralac, have been used in dosages of one trillion CFU/day or more without harmful effects. At very high dosages probiotics may cause diarrhea in some people which can be eliminated by reducing the dose. Sometimes when high potency probiotics are used for the first time a short period of discomfort results while the intestinal tract's microflora is being rebalanced. This is called the Herxheimer Reaction.

The Herxheimer Reaction is a period if discomfort that sometimes results when harmful microorganisms are rapidly killed off in the intestinal tract and their toxic byproducts accumulate prior to elimination. When the intestinal tract is severely out of balance (has low numbers of probiotic bacteria) and one takes a high potency probiotic, it may cause a sudden die off of harmful bacteria (or yeast) followed by detoxification symptoms such as bloating, cramping, gas or headaches. Usually these symptoms subside in a short time as the probiotics gain control and the harmful microorganisms are eliminated. If this happens, stay the course with the probiotic or lessen the dose slightly. If severe or persistent symptoms occur see your doctor.

Gelatin is derived from beef byproducts and is not acceptable to vegetarians. Some non-vegetarians object to beef byproducts for other reasons. Vegicaps are made from materials of plant origin. Theralac does not contain any: milk, yeast, eggs, corn, soy, gluten, wheat, casein, nuts, seafood or beef products.

Scientific and Clinical Studies on Theralac's Probiotic Strains

Lactobacillus paracasei strain F-19 present in Theralac at 5 Billion CFU Per Capsule

References

Deposited at the American Type Culture Collection (ATCC) as SD5275.

Engelbrektson, A.L., Korzenik, J.R., Sanders, M.E., Clement, B.G., Leyer, G., Klaenhammer, T.R. and Kitts, C.L. (2006). Analysis of treatment effects on the microbial ecology of the human intestine. FEMS Microbiol. Ecol. 57:239-250

Paineau, D., Carcano, D., Leyer, G., Darquy, S., Alyanakian, M.A., Simoneau, G., Bergmann, J.F., Brassart, D., Bornet, F. and Ouwehand, A.C. (2008). Effects of seven potential probiotic strains on specific immune responses in healthy adults: a double-blind, randomized, controlled trial. FEMS Immunology & Medical Microbiology 53(1):107-113

Roessler, A. (nee Klein), Friedrich, U., Vogelsang, H., Bauer, A., Kaatz, M.,Hipler, U.C., Schmidt, I. and Jahreis, G. (2007). The immune system in healthy adults and patients with atopic dermatitis seems to be affected differently by a probiotic intervention. Clinical and Experimental Allergy 38:93-102.

List of taxonomic units proposed for QPS status http://www.efsa.europa.eu/en/efsajournal/doc/587.pdf.

Bifidobacterium lactis strain BL-34 (Also called Bl-04) present in Theralac at 10 Billion CFU per Capsule

Human strain on deposit at the American Type Culture Collection (ATCC) as SD5219

Ventura, V. and Zink, R. (2002). Rapid identification, differentiation, and proposed new taxonomic classification of Bifidobacterium lactis. Appl. Environ. Microbiol. 68(12):6429-6434.

B. lactis is on the EU Safety List for Human consumption.

Borriello, S.P., Hammes, W.P., Holzapfel, W., Marteau, J., Schrezenmeir, J., Vaara, M. and Valtonen, V. (2003). Safety of Probiotics That Contain Lactobacilli or Bifidobacteria. Clinical Infect. Disease 36:775-780.

Engelbrektson, A., Korzenik, J.R., Pittler, A., Sanders, M.E., Klaenhammer, T.R., Leyer, G. and Kitts, C.L. (2009). Probiotics to minimize the disruption of faecal microbiotia in healthy subjects undergoing antibiotic therapy. J. Medical Microbiology 58:663-670.

Bartosch, S., Woodmansey, E.J., Paterson, J.C.M., McMurdo, M.E.T. and Macfarlane, G.T. (2005). Microbiological effects of consuming a symbiotic containing Bifidobacterium bifidum, bifidobacterium lactis, and oligofructose in elderly persons, determined by real-time polymerase chain reaction and counting of viable bacteria. Clinical Infect. Diseases. 40:28-37.

Foligne, B., Nutten, S., Grangette, C., Dennin, V., Goudercourt, D., Poiret, S., Dewulf, J., Brassart, D., Mercenier, A. and Pot, B. (2007). Correlation between in vitro and in vivo immunomodulatory properties of lactic acid bacteria. World J. Gastroenterology 13(2):236-243.

Lammers, K.M., Brigidi, P., Vitali, B., Gionchetti, P., Rizello, F., Caramelli, E., Matteuzzi, D. and Campieri, M. (2003). Immunomodulatory effects of probiotic bacteria DNA:IL-1 and IL-10 response in human peripheral blood mononuclear cells. FEMS Immunology and Medical Microbiology 38:165-172.

Bifidobacterium lactis strain Bi-07 present in Theralac at 3 Billion CFU Per Capsule

Complimentary human strain synergistic with BL-34 on deposit at the American Type Culture Collection (ATCC) as SD5220.

Engelbrektson, A., Korzenik, J.R., Pittler, A., Sanders, M.E., Klaenhammer, T.R., Leyer, G. and Kitts, C.L. (2009). Probiotics to minimize the disruption of faecal microbiotia in healthy subjects undergoing antibiotic therapy. J. Medical Microbiology 58:663-670.

Ventura, V. and Zink, R. (2002). Rapid identification, differentiation, and proposed new taxonomic classification of Bifidobacterium lactis. Appl. Environ. Microbiol. 68(12):6429-6434.

Foligne, B., Nutten, S., Grangette, C., Dennin, V., Goudercourt, D., Poiret, S., Dewulf, J., Brassart, D., Mercenier, A. and Pot, B. (2007). Correlation between in vitro and in vivo immunomodulatory properties of lactic acid bacteria. World J. Gastroenterology 13(2):236-243.

Wagner, R.D., Pierson, C., Warner, T., Dohnalek, M., Farmer, J., Roberts, L., Hilty, M. and Balish, E. (1997). Biotherapeutic effects of probiotic bacteria on candidiasis in immunodeficient mice. Infect. Immun. 65:4165-4172.

Ruiz-Palacios, G.F., Guerrero, M., Hilty, M., Dohnalek, P., Newton, P., Calva, J.J., Tostigan, T., Tuz, F. and Arteaga, M.L. (1999). Feeding of a probiotic for the prevention of community acquired diarrhea in young Mexican children. Pediatr. Res. 39(2):104 (abstr).

Provisional Patent Application. Ser. No. 60/848,662 filed on 2 October 2006.

Lactobacillus rhamnosus strain LR-44 present in Theralac at 2 Billion CFU Per Capsule

Deposited at the American Type Culture Collection (ATCC) as SD5217.

Collins, M.D., Phillips, B.A. and Zanoni, P. (1989). Deoxy-ribonucleic acid homology studies of Lactobacillus casei, Lactobacillus paracasei sp. nov. subsp. Paracasei and subsp. Tolerans and Lactobacillus rhamnosus sp. nov. comb. nov. International Journal of Systemic Bacteriology 39:105-108.

Foligne, B., Nutten, S., Grangette, C., Dennin, V., Goudercourt, D., Poiret, S., Dewulf, J., Brassart, D., Mercenier, A. and Pot, B. (2007). Correlation between in vitro and in vivo immunomodulatory properties of lactic acid bacteria. World Journal of Gastroenterology. 13(2):236-243.

Foligne, B., Zoumpopoulou, G., Dewulf, J., Ben Younes, A., Chareyre, F., Sirard, J.-C., Pot, B. and Grangette, C. (2007). A Key Role of Dendritic Cells in Probiotic Functionality. PloS ONE 2(3):e313. doi:10.137l/journal.pone.0000313.

List of taxonomic units proposed for QPS status http://www.efsa.europa.eu/en/efsajournal/doc/587.pdf.

Lactobacillus acidophilus strain LA-1 (10 Billion CFU per Capsule)

Note: Some references refer to this strain as LA-5. Bifidobacterium TB-12 is also included in some of the references cited for LA-1.

Human strain on deposit at the American Type Culture Collection (ATCC) as SD5221.

Wagner R., Warner, T.,Robert, L., Farmer, J. and Balish, E. (1997). Colonization of congenitally immunodeficient mice with probiotic bacteria. Infect. Immun. 65:3345-3351.

Sui, J., Leighton, S., Busta, F. and Brady L. (2002). 16s ribosomal DNA analysis of the fecal lactobacilli composition on human subjects consuming a probiotic strain Lactobacillus acidophilus NCFM. J. Appl. Microbiol. 93:907-912.

Varcoe, J., Zook, C., Sui, J., Leighton, S., Busta, F. and Brady L. (2002) Variable response to exogenous Lactobacillus acidophilus NCFM consumed in different vehicles. J. Appl. Microbiol. 93:900-906.

Greene, J.D. and Klaenhammer, T.R. (1994). Factors involved in adherence of lactobacilli to human Caco-2 cells. Appl. Environ. Microbiol. 60:4487-4494.

Kleeman, E.G. and Klaenhammer, T.R. (1982). Adherence of Lactobacillus species to human fetal intestinal cells. J. Dairy Sci. 65:2063-2069.

Gilliland, S.E., and Speck, M.L. (1977). Deconjugation of Bile Acids by Intestional Lactobacilli. Appl. Environ. Microbiol., 33(1):15-18.

Goldin, B.R., Swenson, L., Dwyer, J., Sexton, M. and Gorbach, S.L. (1980). Effect of diet and Lactobacillus acidophilus supplements on human fecal bacterial enzymes. J. Natl. Cancer Inst. 64(2):255-261.

Varcoe, J.J., Krejcarek, G., Busta, F. and Brady, L. (2003). Prophylactic feeding of Lactobacillus acidophilus NCFM to mice attenuates overt colonic hyperplasia. J. Food Prot. 66(3):457-465.

Kim, H.S. and Gilliland, S.E. (1983). Lactobacillus acidophilus as a dietary adjunct for milk to aid lactose digestion in humans. J. Dairy Science. 66(5):959-966.

Dunn, S.R., Simenhoff, M.L., Ahmed, K.E., Gaughan, W.J., Eltayeb, B.O., Fitzpatrick, M.-E.D., Emery, S.M., Ayres, J.W. and Holt, K.E. (1998). Effect of oral administration of freeze-dried Lactobacillus acidophilus on small bowel bacterial overgrowth in patients with end stage kidney disease: reducing uremic toxins and improving nutrition. Int. Dairy J. 8:545-553.

Wagner, R.D., Pierson, C., Warner, T., Dohnalek, M., Farmer, J., Roberts, L., Hilty, M. and Balish, E. (1997). Biotherapeutic effects of probiotic bacteria on candidasis in immunodeficient mice. Infect. Immun. 65(10):4165-4172.

Tejada-Simon, M.V., Lee, J.H., Ustunol, Z. and Pestka, J.J. (1999). Injestion of yogurt containing Lactobacillus acidophilus and Bifidobacterium to potentiate immunoglobulin. A response to cholera in mice. J. Dairy Sci. 82:649-660.

Wagner, R.D., Pierson, C., Warner, T., Dohnalek, M., Hilty, M. and Balish, E. (2000). Probiotic effects of feeding heat-killed Lactobacillus acidophilus and Lactobacillus casei to Candida albicans-colonized immunodeficient mice. J. Food Prot. 63(5):638-644.

Engelbrektson, A., Korzenik, J.R., Pittler, A., Sanders, M.E., Klaenhammer, T.R., Leyer, G. and Kitts, C.L. (2009). Probiotics to minimize the disruption of faecal microbiotia in healthy subjects undergoing antibiotic therapy. J. Medical Microbiology 58:663-670.

Sanders, M.E., Walker, D.C., Walker, K.M., Aoyama, K. and Klaenhammer, T.R. (1996). Performance of commercial cultures in fluid milk applications. J. Dairy Sci. 79:943-955. (Strain LH1=NCFM).

Visit Our Store to Buy Theralac